Disease control and toxicity outcomes for T4 carcinoma of the nasopharynx treated with intensity-modulated radiotherapy

被引:18
|
作者
Takiar, Vinita [1 ]
Ma, Dominic [1 ]
Garden, Adam S. [1 ]
Li, Jing [1 ]
Rosenthal, David I. [1 ]
Beadle, Beth M. [1 ]
Frank, Steven J. [1 ]
Fuller, Clifton D. [1 ]
Gunn, Gary B. [1 ]
Morrison, William H. [1 ]
Hutcheson, Kate [2 ]
El-Naggar, Adel K. [3 ]
Gold, Kathryn A. [4 ]
Kupferman, Michael E. [2 ]
Phan, Jack [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, 1515 Holcombe Blvd,Unit 0097, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Med Oncol, Houston, TX 77030 USA
关键词
nasopharyngeal carcinoma; toxicities; intensity-modulated radiation therapy (IMRT); chemotherapy; temporal lobe necrosis; TEMPORAL-LOBE NECROSIS; RADIATION-THERAPY IMRT; RANDOMIZED PHASE-II; ADJUVANT CHEMOTHERAPY; INDUCTION CHEMOTHERAPY; CANCER; CHEMORADIOTHERAPY; TRIAL; NEOADJUVANT; CISPLATIN;
D O I
10.1002/hed.24128
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Background. Treatment of T4 nasopharyngeal carcinoma (NPC) is challenging because of the proximity of the tumor to the central nervous system. The purpose of this study was to present our evaluation of disease control and toxicity outcomes for patients with T4 NPC treated with intensity-modulated radiation therapy (IMRT) and chemotherapy. Methods. The medical records of 66 patients with T4 NPC treated from 2002 to 2012 with IMRT were reviewed. Endpoints included tumor control and toxicity outcomes (Common Terminology Criteria for Adverse Events [CTCAE v4.0]). Results. Median follow-up was 38 months. Five-year rates of locoregional control, distant metastasis-free survival, progression-free survival (PFS), and overall survival (OS) were 80%, 62%, 57%, and 69%, respectively. Nodal involvement was associated with worse PFS (p=.015). Gross target volume (GTV) volume > 100 cm and planning target volume (PTV) volume > 400 cm were associated with worse OS (p=.038 and p=.004, respectively). Four patients had significant cognitive impairment, and 9 had MRI evidence of brain necrosis. Conclusion. For patients with T4 NPC treated with IMRT and chemotherapy, survival and locoregional disease control rates have improved; however, late treatment toxicity remains a concern. (c) 2015 Wiley Periodicals, Inc.
引用
收藏
页码:E925 / E933
页数:9
相关论文
共 50 条
  • [31] Long-Term Results of Intensity-Modulated Radiotherapy for T4 Nasopharyngeal Carcinoma: New Insight into the Value of Concurrent Chemotherapy
    Kong, Fangfang
    Zhai, Ruiping
    Huang, Juan
    Ying, Hongmei
    Hu, Chaosu
    CANCER INVESTIGATION, 2021, 39 (08) : 645 - 652
  • [32] Ten-Year Results Of Intensity-Modulated Radiotherapy For T4 Nasopharyngeal Carcinoma: New Insight Into The Value Of Concurrent Chemotherapy
    Kong, F. F.
    Zhai, R. P.
    Huang, J.
    Ye, L. L.
    Oei, R. W.
    Du, C.
    Ying, H. M.
    Hu, C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E839 - E839
  • [33] Dosimetric predictors of temporal lobe injury after intensity-modulated radiotherapy for T4 nasopharyngeal carcinoma: a competing risk study
    Huang, Juan
    Kong, Fang-fang
    Oei, Ronald Wihal
    Zhai, Rui-ping
    Hu, Chao-su
    Ying, Hong-mei
    RADIATION ONCOLOGY, 2019, 14 (1)
  • [34] Treatment Outcomes of Helical Intensity-Modulated Radiotherapy for Unresectable Hepatocellular Carcinoma
    Kong, Moonkyoo
    Hong, Seong Eon
    Choi, Woo Suk
    Choi, Jinhyun
    Kim, Youngkyong
    GUT AND LIVER, 2013, 7 (03) : 343 - 351
  • [35] ACUTE TOXICITY IN PROSTATE CANCER PATIENTS TREATED WITH HYPOFRACTIONATED INTENSITY-MODULATED RADIOTHERAPY
    Bellavita, Rita
    Raymondi, Carlo
    Matrone, Fabio
    Massetti, Michela
    Lupattelli, Marco
    Arcidiacono, Fabio
    Mearini, Luigi
    Zucchetti, Claudio
    Palumbo, Isabella
    Aristei, Cynthia
    ANTICANCER RESEARCH, 2011, 31 (05) : 1912 - 1912
  • [36] Intensity-modulated radiation therapy for T4 nasopharyngeal carcinoma Treatment results and locoregional recurrence
    Chen, J. L. -Y.
    Huang, Y. -S.
    Kuo, S-H.
    Chen, Y. -F.
    Hong, R. -L.
    Ko, J. -Y.
    Lou, P. -J.
    Tsai, C. -L.
    Chen, W. -Y.
    Wang, C. -W.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2013, 189 (12) : 1001 - 1008
  • [37] Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Oropharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy
    Youssef, Irini
    Yoon, Jennifer
    Mohamed, Nader
    Zakeri, Kaveh
    Press, Robert H.
    Chen, Linda
    Gelblum, Daphna Y.
    McBride, Sean M.
    Tsai, Chiaojung Jillian
    Riaz, Nadeem
    Yu, Yao
    Cohen, Marc A.
    Dunn, Lara Ann
    Ho, Alan L.
    Wong, Richard J.
    Michel, Loren S.
    Boyle, Jay O.
    Singh, Bhuvanesh
    Kriplani, Anuja
    Ganly, Ian
    Sherman, Eric J.
    Pfister, David G.
    Fetten, James
    Lee, Nancy Y.
    JAMA NETWORK OPEN, 2022, 5 (11) : E2241538
  • [38] Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy
    Li, Xingzhe
    Kitpanit, Sarin
    Lee, Anna
    Mah, Dennis
    Sine, Kevin
    Sherman, Eric J.
    Dunn, Lara A.
    Michel, Loren S.
    Fetten, James
    Zakeri, Kaveh
    Yu, Yao
    Chen, Linda
    Kang, Jung Julie
    Gelblum, Daphna Y.
    McBride, Sean M.
    Tsai, Chiaojung J.
    Riaz, Nadeem
    Lee, Nancy Y.
    JAMA NETWORK OPEN, 2021, 4 (06)
  • [39] Outcomes and prognostic factors of conformal radiotherapy versus intensity-modulated radiotherapy for nasopharyngeal carcinoma
    Wei Lu Kuang
    Qin Zhou
    Liang Fang Shen
    Clinical and Translational Oncology, 2012, 14 : 783 - 790
  • [40] Outcomes and prognostic factors of conformal radiotherapy versus intensity-modulated radiotherapy for nasopharyngeal carcinoma
    Kuang, Wei Lu
    Zhou, Qin
    Shen, Liang Fang
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2012, 14 (10): : 783 - 790